JPH0733624A - Agent for treating and preventing acne - Google Patents
Agent for treating and preventing acneInfo
- Publication number
- JPH0733624A JPH0733624A JP20045493A JP20045493A JPH0733624A JP H0733624 A JPH0733624 A JP H0733624A JP 20045493 A JP20045493 A JP 20045493A JP 20045493 A JP20045493 A JP 20045493A JP H0733624 A JPH0733624 A JP H0733624A
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl compound
- acne
- treating
- propionibacterium acnes
- antibacterial action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、医薬品、医薬部外品、
化粧品などに配合され、プロピオニバクテリウム アク
ネスに対して強い抗菌作用を有する特定のビフェニル化
合物に関する。BACKGROUND OF THE INVENTION The present invention relates to pharmaceuticals, quasi drugs,
The present invention relates to a specific biphenyl compound that is incorporated into cosmetics and has a strong antibacterial action against Propionibacterium acnes.
【0002】[0002]
【従来の技術】ニキビの病因はいまだに解明されていな
いが、思春期に起こるホルモン活性の増加に伴う分泌過
多の皮脂が未成熟な毛漏斗に充満し、毛嚢皮脂腺の閉塞
を起こす結果、嫌気性菌プロピオニバクテリウム アク
ネス(Propionibacterium acnes)の異常増殖が関与して
いると考えられている。このため、ニキビ治療や予防剤
として、エリスロマイシン、テトラサイクリン、クリン
ダマイシン等の抗生物質やイオウ、カンフル、サルファ
剤等の角質の剥離によるニキビの自然治癒を期待するも
のが用いられてきた。BACKGROUND OF THE INVENTION Although the etiology of acne has not yet been elucidated, hypersecreted sebum associated with increased hormonal activity during puberty fills the immature hair funnel, causing obstruction of the pilosebaceous sebaceous gland, resulting in anaerobic It is considered that the abnormal growth of the sex bacterium Propionibacterium acnes is involved. Therefore, as an anti-acne treatment or preventive agent, antibiotics such as erythromycin, tetracycline, and clindamycin, and sulfur, camphor, and sulfa drugs, which are expected to cure acne naturally, have been used.
【0003】しかしながら、エリスロマイシン、テトラ
サイクリン、クリンダマイシン等の抗生物質は、胃腸障
害などの強い副作用を示すことが知られている。一方、
イオウ、カンフル、サルファ剤等の剥離作用は度重なる
塗布により、ニキビ周囲の皮膚に刺激を与えること、ま
た治療効果の個人差が大きく、充分な治療及び予防効果
があるとはいえない。However, it is known that antibiotics such as erythromycin, tetracycline and clindamycin show strong side effects such as gastrointestinal disorders. on the other hand,
The stripping action of sulfur, camphor, sulfa, etc. causes irritation to the skin around the acne by repeated application, and there are large individual differences in the therapeutic effect, and it cannot be said that there is a sufficient therapeutic and preventive effect.
【0004】[0004]
【発明が解決しようとする課題】本発明者らは、上記事
情を鑑み、プロピオニバクテリウム アクネスに対して
強い抗菌活性を有する化合物について鋭意検討した。そ
の結果、特定のビフェニル化合物が、プロピオニバクテ
リウム アクネスに対して強い抗菌作用を有しているこ
とを見いだした。In view of the above circumstances, the present inventors have made extensive studies on compounds having a strong antibacterial activity against Propionibacterium acnes. As a result, it was found that a specific biphenyl compound has a strong antibacterial action against Propionibacterium acnes.
【0005】したがって本発明の目的は、プロピオニバ
クテリウム アクネスに対して強い抗菌作用を有する化
合物を提供することにある。Therefore, an object of the present invention is to provide a compound having a strong antibacterial action against Propionibacterium acnes.
【0006】[0006]
【課題を解決するための手段】即ち、本発明は下記一般
式Means for Solving the Problems That is, the present invention has the following general formula:
【0007】[0007]
【化2】 [Chemical 2]
【0008】(但しRは水素原子もしくは炭素数1から
8の直鎖及び分岐鎖状の飽和炭化水素基)で表されるビ
フェニル化合物からなるニキビ治療及び予防剤に関す
る。The present invention relates to an agent for treating and preventing acne, which comprises a biphenyl compound represented by a hydrogen atom or a linear or branched saturated hydrocarbon group having 1 to 8 carbon atoms.
【0009】本発明に使用されるビフェニル化合物の一
部は公知の物質が含まれ、その合成方法について報告さ
れている(日本化学雑誌第87巻、第6号、603頁、
1966年)。また、それ以外の化合物も同様の合成方
法によって得ることが出来る。A part of the biphenyl compound used in the present invention contains known substances, and a method for synthesizing the same has been reported (Japan Chemical Journal Vol. 87, No. 6, p. 603,
1966). Further, other compounds can be obtained by the same synthetic method.
【0010】本発明のニキビ治療及び予防剤は、例えば
医薬品・医薬部外品・化粧品などに配合することが可能
である。The acne treatment and prevention agent of the present invention can be incorporated into, for example, pharmaceuticals, quasi drugs, cosmetics and the like.
【0011】その配合量は使用する系によって異なり、
一概には言えないが、以下の実施例から明らかなよう
に、既存のこの種の物質とでよい。The blending amount depends on the system used,
Although it cannot be said to be unequivocal, as will be apparent from the following examples, an existing substance of this type may be used.
【0012】次に、本発明のビフェニル化合物によるプ
ロピオニバクテリウム アクネスに対する抗菌作用の効
果を明らかにするための実施例を示す。Next, examples for clarifying the effect of the antibacterial action against Propionibacterium acnes by the biphenyl compound of the present invention will be shown.
【0013】[0013]
【実施例】 以下、実
施例について説明する。実施例におけるビフェニル化合
物の名称を前記一般式のRの違いにより以下の如く略記
する。ビフェニル化合物1(R=CH3 )、ビフェニル
化合物2(R=C2 H5 )、ビフェニル化合物3(R=
C3 H7 )、ビフェニル化合物4(R=iso−C3H
7 )、ビフェニル化合物5(R=C8 H17)、ビフェニ
ル化合物6(R=H)。また、構造の異なるビフェニル
化合物であるデヒドロジオイゲノール、デヒドロジクレ
オソールを対照として用いた。EXAMPLES Examples will be described below. The names of the biphenyl compounds in the examples are abbreviated as follows depending on the difference in R in the general formula. Biphenyl compounds 1 (R = CH 3), biphenyl compounds 2 (R = C 2 H 5 ), biphenyl compounds 3 (R =
C 3 H 7 ), biphenyl compound 4 (R = iso-C 3 H
7), biphenyl compounds 5 (R = C 8 H 17 ), biphenyl compounds 6 (R = H). In addition, dehydrodioigenol and dehydrodicresol, which are biphenyl compounds having different structures, were used as controls.
【0014】〔抗菌作用試験方法〕プロピオニバクテリ
ウム アクネスに対する抗菌作用を試験する方法として
ペーパーディスク法を用いて行った。寒天培地に、別に
同液体培地で培養しておいたプロピオニバクテリウム
アクネス培養液を混合(0.1ml/100ml培地)
し、10mlをシャーレに分注固化した。シャーレの中
央にペーパーディスクを置き、試料の無水エタノール溶
液(容量%、以下%と略)50μlを滴下した。5℃に
て24時間静置した後、32℃にて48時間培養した。
ペーパーディスクのまわりに形成された阻止円の直径を
測定する事により、抗菌力を調べた。測定に用いたサン
プル濃度は1.25、0.625、0.313および
0.156%で行った。[Test Method for Antibacterial Action] As a method for testing the antibacterial action against Propionibacterium acnes, the paper disc method was used. Propionibacterium cultivated separately in the same liquid medium on the agar medium
Mix Acnes culture solution (0.1 ml / 100 ml medium)
Then, 10 ml was dispensed and solidified in a petri dish. A paper disk was placed in the center of the petri dish, and 50 μl of a sample absolute ethanol solution (volume%, abbreviated as%) was dropped. After standing at 5 ° C. for 24 hours, it was cultured at 32 ° C. for 48 hours.
The antibacterial activity was investigated by measuring the diameter of the inhibition circle formed around the paper disc. The sample concentrations used for the measurement were 1.25, 0.625, 0.313 and 0.156%.
【0015】[0015]
【表1】 [Table 1]
【0016】表1の結果から、本発明のビフェニル化合
物は、濃度依存的にプロピオニバクテリウム アクネス
に対して抗菌作用を有し、しかも低濃度で効果のあるこ
とがわかった。From the results shown in Table 1, it was found that the biphenyl compound of the present invention has a concentration-dependent antibacterial action against Propionibacterium acnes and is effective even at low concentrations.
【0017】[0017]
【発明の効果】以上記載の如く、本発明が低濃度でプロ
ピオニバクテリウム アクネスに対して強い抗菌作用を
有することから、ニキビを治療もしくは予防するための
化粧品、医薬部外化粧料や薬品への配合が可能であり、
有用なニキビ治療及び予防剤を提供することは明かであ
る。As described above, since the present invention has a strong antibacterial action against Propionibacterium acnes at a low concentration, it can be applied to cosmetics, quasi-cosmetics and drugs for treating or preventing acne. It is possible to mix
It is clear to provide useful acne treatment and prevention agents.
Claims (1)
からなるニキビ治療及び予防剤。 【化1】 (但しRは水素原子もしくは炭素数1から8の直鎖及び
分岐鎖状の飽和炭化水素基)1. A therapeutic and prophylactic agent for acne comprising a biphenyl compound represented by the following general formula. [Chemical 1] (However, R is a hydrogen atom or a linear or branched saturated hydrocarbon group having 1 to 8 carbon atoms)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20045493A JP2719301B2 (en) | 1993-07-19 | 1993-07-19 | Acne treatment and prevention agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20045493A JP2719301B2 (en) | 1993-07-19 | 1993-07-19 | Acne treatment and prevention agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0733624A true JPH0733624A (en) | 1995-02-03 |
JP2719301B2 JP2719301B2 (en) | 1998-02-25 |
Family
ID=16424577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20045493A Expired - Fee Related JP2719301B2 (en) | 1993-07-19 | 1993-07-19 | Acne treatment and prevention agents |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2719301B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097314B2 (en) | 2007-05-10 | 2012-01-17 | Gunze Limited | Fluororesin tube and process for producing the same |
US20140328772A1 (en) * | 2011-12-15 | 2014-11-06 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US20140341818A1 (en) * | 2011-12-15 | 2014-11-20 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US20140348761A1 (en) * | 2011-12-15 | 2014-11-27 | Colgate-Palmolive Company | Solubilized magnolol analogs |
-
1993
- 1993-07-19 JP JP20045493A patent/JP2719301B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097314B2 (en) | 2007-05-10 | 2012-01-17 | Gunze Limited | Fluororesin tube and process for producing the same |
US20140328772A1 (en) * | 2011-12-15 | 2014-11-06 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US20140341818A1 (en) * | 2011-12-15 | 2014-11-20 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US20140348761A1 (en) * | 2011-12-15 | 2014-11-27 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US9155693B2 (en) * | 2011-12-15 | 2015-10-13 | Colgate-Palmolive Company | Solubilized magnolol analogs |
US9414587B2 (en) * | 2011-12-15 | 2016-08-16 | Cologne-Palmolive Company | Solubilized magnolol analogs |
Also Published As
Publication number | Publication date |
---|---|
JP2719301B2 (en) | 1998-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wilk et al. | Cerebrospinal fluid levels of MHPG in affective disorders | |
US3969516A (en) | Composition and method for treatment of acne | |
CN102341105B (en) | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications | |
JPS59134726A (en) | Storage stable local drug composition containing low dielectric solvent | |
CA1221032A (en) | Composition for reducing sebum secretion | |
US4520133A (en) | Monohydroxy-benzoyl peroxide and compositions for treating acne | |
JPH0733649A (en) | Anticarious agent | |
JPH0733624A (en) | Agent for treating and preventing acne | |
JP2530488B2 (en) | Cosmetics | |
WO2018084112A1 (en) | Acne strain-selective antibacterial agent | |
JPH11302143A (en) | Enhancer of barrier strength against permeation through skin, and cosmetic | |
JPH0255404B2 (en) | ||
KR20190114921A (en) | Ph-sensitive cosmetic composition for improving acne and manufacturing method thereof | |
JP2007521239A (en) | Antibacterial composition and method of use | |
WO2001070235A1 (en) | Composition based on sphingolipid and beta-hydroxy-acid for skin care | |
CN116322624A (en) | Composition for promoting skin microbiota | |
JPH09278638A (en) | Agent for treating and preventing tragomaschalia | |
CN104758242B (en) | A kind of sodium fusidate ointment pharmaceutical composition and preparation method thereof | |
JPH0692293B2 (en) | External skin preparation | |
KR100570847B1 (en) | Acne skin composition | |
US6403111B1 (en) | Method for preparing aqueous phytosphingosine solution | |
WO2014164806A1 (en) | Preservative system | |
US3651218A (en) | Antifungal compositions | |
KR101198106B1 (en) | Antimicrobial composition comprising synthesized gallol derivatives with effects of antioxidant and inhibition of lipid peroxidation | |
JPH0692296B2 (en) | External skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 12 Free format text: PAYMENT UNTIL: 20091114 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 13 Free format text: PAYMENT UNTIL: 20101114 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111114 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 15 Free format text: PAYMENT UNTIL: 20121114 |
|
LAPS | Cancellation because of no payment of annual fees |